![]() Music |
![]() Video |
![]() Movies |
![]() Chart |
![]() Show |
![]() |
CheckMate 274: OS Outcomes for Patients With MIBC (GU Oncology Now) View |
![]() |
CheckMate 274 u0026 EV-301: highlights in UC from ASCO GU (VJOncology) View |
![]() |
Checkmate 274 Adjuvant Nivolumab in Urothelial Cancer | An Oncologist's Take (Vinay Prasad MD MPH) View |
![]() |
ASCO GU Bladder Updates: EV-302, CheckMate 274, and More (GU Oncology Now) View |
![]() |
The OS results of the CheckMate 274 study, showing benefit trends from adjuvant immunotherapy (Mediamedic) View |
![]() |
Adjuvant Therapy Challenges: When to Rechallenge Immunotherapy and Chemotherapy in Bladder Cancer (GU Oncology Now) View |
![]() |
Expert video report on Urothelial Carcinoma from 2021 Genitourinary Cancers Symposium (European Society for Medical Oncology (ESMO)) View |
![]() |
Post-EV/Pembro Progression: How Real-World Data is Shaping 2L Treatment Decisions (GU Oncology Now) View |
![]() |
Key updates in bladder cancer from ASCO GU 2021 (VJOncology) View |
![]() |
POUT: extended follow-up results (VJOncology) View |